<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6470">
  <stage>Registered</stage>
  <submitdate>28/03/2017</submitdate>
  <approvaldate>28/03/2017</approvaldate>
  <nctid>NCT03108274</nctid>
  <trial_identification>
    <studytitle>A Phase I DDI Study Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil</studytitle>
    <scientifictitle>A Three-Part Phase I Study to Determine the Potential Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>U1111-1193-2774</secondaryid>
    <secondaryid>ACH471-010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Drug Interaction Potentiation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Part 1, Period 1
Treatment: drugs - Part 1, Period 2
Treatment: drugs - Part 2, Period 1
Treatment: drugs - Part 2, Period 2
Treatment: drugs - Part 3, Period 1
Treatment: drugs - Part 3, Period 2

Experimental: Part 1, Period 1 - Single oral dose of Midazolam Day 1

Experimental: Part 1, Period 2 - Multiple oral doses of ACH-0144471 Day 1-4 Single oral single dose of Midazolam on Day 4

Experimental: Part 2, Period 1 - Single dose of Fexofenadine on Day 1

Experimental: Part 2, Period 2 - Multiple doses of ACH-0144471 on Days 1-6 Single dose of Fexofenadine on Day 4

Experimental: Part 3, Period 1 - Single dose of Mycophenolate Mofetil on Day 1

Experimental: Part 3, Period 2 - Multiple doses of ACH-0144471 on Days 1-6 Single dose of Mycophenolate Mofetil on Day 4


Treatment: drugs: Part 1, Period 1
Midazolam single oral dose

Treatment: drugs: Part 1, Period 2
Multiple doses ACH-0144471 Single dose Midazolam

Treatment: drugs: Part 2, Period 1
Fexofenadine single oral dose

Treatment: drugs: Part 2, Period 2
Multiple doses ACH-0144471 Single dose Fexofenadine

Treatment: drugs: Part 3, Period 1
Mycophenolate Mofetil single oral dose

Treatment: drugs: Part 3, Period 2
Multiple doses ACH-0144471 Single dose Mycophenolate Mofetil

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil - To determine the effect of multiple oral doses of ACH-0144471 on the pharmacokinetics (PK) of midazolam, fexofenadine and mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) as measured by maximum observed concentration (Cmax)</outcome>
      <timepoint>Up to 26 Days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil - To determine the effect of multiple oral doses of ACH-0144471 on the pharmacokinetics (PK) of midazolam, fexofenadine and mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) as measured by area under the curve (AUC)</outcome>
      <timepoint>Up to 26 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Drug Interaction Between ACH-0144471 and Midazolam - To assess the safety and tolerability of multiple oral doses of ACH-0144471 with midazolam measured by adverse events (AE's), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG)</outcome>
      <timepoint>Up to 26 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Drug Interaction Between ACH-0144471 and Fexofenadine - To assess the safety and tolerability of multiple oral doses of ACH-0144471 with fexofenadine measured by adverse events (AE's), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG)</outcome>
      <timepoint>Up to 26 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Drug Interaction Between ACH-0144471 and Mycophenolate Mofetil - To assess the safety and tolerability of multiple oral doses of ACH-0144471 with mycophenolate mofetil measured by adverse events (AE's), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG)</outcome>
      <timepoint>Up to 26 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy male and female subjects age 18-60

          -  Have a BMI of 18.5 to 32 kg/m2 with a minimum body weight of 50kg

          -  Females must be of non-childbearing potential

          -  Males must agree to use effective contraception during and for 90 days after last dose
             of study drug

          -  Willing to answer inclusion and exclusion criteria

          -  Give voluntary consent

          -  Willing to comply with visit schedule and all procedures and tests</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Mentally or legally incapacitated or significant emotional problems

          -  History of disease

          -  Any condition which might interfere with drug absorption

          -  Positive test for HIV, Hepatitis B and/or C

          -  History of sensitivity to study medication, or other drug allergy

          -  Body temperature greater than 38 Celsius

          -  History of febrile illness within 14 days of first dose

          -  History of meningococcal infection

          -  Positive urine drug test

          -  Current tobacco users and smokers

          -  Consumption of alcohol within 72 hours of study drug administration

          -  Participated in another clinical study within 28 days prior to first dose

          -  Previous participation in an ACH-0144471 study

          -  12-lead ECG with significant findings

          -  Significant laboratory abnormalities

          -  Use of prescription medications within 14 days of first dose

          -  Use of medications known to induce hepatic microsomal enzyme cytochrome

          -  Prior history or current evidence of biliary cholestasis

          -  Blood donation of more than 500mL within 3 months of first dose

          -  Received a blood transfusion or blood products within 6 months to first dose

          -  Unwilling or unable to comply with study protocol

          -  Males subjects with female partner who is pregnant, nursing or planning to become
             pregnant within 90 days of last study dose

          -  Received live attenuated vaccine within 30 days or other vaccine within 14 days of
             first dose

          -  Have or history of Gilberts syndrome</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>18/04/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>35</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>16/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Achillion Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the potential drug interaction between ACH-0144471
      and Midazolam, Fexofenadine and Mycophenolate Mofetil</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03108274</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Hamilton, MD</name>
      <address>Auckland Clinical Studies Limited</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>